The aim of the study was to investigate the predictive value of circulating matrix metalloproteinase-9 (MMP-9) in hypertensive patients after acute ischemic stroke. Methods. 102 patients with mild to moderate arterial hypertension within 3 weeks after acute ischemic stroke were included in the study. Follow-up was 12 months with a 3 month intervals. The circulating MMP-9 level was assessed at baseline.
Introduction
Arterial hypertension and proinflammatory activation are shared risk factors for atherosclerotic disease and stroke [1] . High levels of inflammatory biomarkers, such as C-reactive protein, matrix metalloproteinases (MMP), in hypertensive population and in patients with acute stroke are known to be associated with subsequent atherothrombotic events [2, 3] . MMP-9 mediates collagen deposition, gelatinases activity and it may play roles in cardiovascular disease [4] . However, prognostic role of peak concentration of MMP-9 in hyprtensive patients after acute ischemic stroke is still not understood. The aim of the study was to investigate the predictive value of serial measurements of circulating MMP-9 level for recurrent cardiovascular events in hypertensive patients after ischemic stroke.
Methods
It has been enrolled 102 patients with mild-to-moderate arterial hypertension in 3 weeks after acute ischemic stroke. All patients gave a written informed consent to participate in the study. Neurological impairment at presentaPredicted value of circulating matrix metalloproteinase-9 3 tion was assessed by National Institute of Health Stroke Scale (NIHSS) (National Institute of Health Stroke Scale) [5] . The type of acute ischemic stroke was classified according to the TOAST classification [6] . The Barthel Index and the modified Rankin Scale were used to assess functional disability [6] . The functional outcome using these scales was evaluated at admission and on the 21 st day of acute period of stroke before including to the study. Contrast-enhanced computer spiral tomography (CT) was performed on a "Somatom Spirit" scanner (Siemens, Germany). Nonionic contrast "Omnipak" (Amersham Health, Ireland) was used.
All blood samples were collected in cooling vacutaner and after that it was immediately centrifuged (4°C for 6.000 × 15 min). After centrifugation serum was blind coded and stored at -70° until used. MMP-9 was measured by ELISA at baseline of observation with commercial laboratory kits manufacturing R & D (R & D System Europe, Ltd; United Kingdom). High-sensitivity C-RP levels were measured by nephelometric technique and obtained with "AU640 Analyzer" (Olympus Diagnostic Systems Group, Japan). Concentrations of total and HDL cholesterol were determined by a Dimension Clinical Chemistry System (Dade Behring Inc, Newark, NJ). LDL cholesterol was calculated by using the formula of Friedewald W.T., Levy R.I., Fredrickson D.S. (1972) .
Statistical Analysis
All statistical analyses were performed in SPSS for Windows v. 17.0 (SPSS Inc., Chicago, Il, USA). All values were given as mean and 95% CI or median and percentiles. An independent group t-test was used for comparisons for all interval parameters meeting the criteria of normality and homogeneity of variance. For interval parameters not meeting these criteria, the non-paramentric Mann-Whitney test was used to make comparisons between groups. Comparisons of categorical variables between groups were performed using the Chi 2 test, and the Fisher exact test. Receiver operating characteristic (ROC) curves were configured to establish cutoff points of MMP-9 levels that optimally predicted the occurrence of cumulative clinical events. A calculated difference of P<0.05 was considered significant.
Results and Discussion
One hundred two mild-to-moderate arterial hypertension patients (67 men and 35 women; mean age, 58.38 years [95% CI = 54-72 years]) were included in this study in 3 weeks after first clinical signs of ischemic stroke. Baseline characteristics of the study group are presented in Table 1 . All included patients were hypertensive at the screening (78 subjects with mild hypertension, and 24 subjects with moderated hypertension). All patients were included in the study after achieved goal blood pressure (less than 140 / 90 mm Hg). Besides 45.1% enrolled subjects were dyslipemic, 42.2% patients were smoked, and 14.7% patients had a history of mild diabetes mellitus. Median of hs-CRP concentration was 5.91 mg/L (95% CI=2.90-10.55 mg/L). There was a significantly increased median of hs-CRP concentration in cohort with clinical events (Me=7,24 mg/L, 95% CI =4,43-10,21 mg/L) when compared with free clinical events cohort (Me=4,47 mg/L, 95% CI =3,60-5,80 mg/L; P=0.012). T2DM was occurred a much higher in cohort with clinical events when compared with free clinical events patients. Total cholesterol plasma level was a significant higher in cohort patients with clinical event occurred in comparison to free-event patients. Treatment strategy was similar in both cohorts, but there was a significant increased frequency of agntiaggregants distinguished form aspirin in patients with clinical events occurred. Statins before admission were prescribed much often in free-events cohort patients. It has taken into consideration that at the study entry proportions of the patients with statins prescribing was similar. Target levels of LDL-C less 1.8 mmol/L and less 2.5 mmol/L were achieved in 23 (22.5%) and 33 (32.4%) patients at the study entry. Note: T2DM -type two diabetes mellitus, NIHSS -National Institute of Health Stroke Scale, LAC -lacunar infarct, LAAS -Large Artery AtheroSclerosis, CEICardioEmbolic Infarct, BMI -body mass index, LDL -low density lipoprotein, hs-CRP -high-sensitivity C-reactive protein, * -significance differences between cohorts (P<0.05). All subjects before study entry were hemodynamically stable and they have controlled arterial hypertension and remained free of any ischemic events during the time elapsed between the first qualifying episode and the inclusion visit date. During observation period 57 cumulative clinical events occurred and they were identified in 48 patients (47.1%). They were distributed in 4 deaths, 6 cardiac arrhythmias, 17 cardiac ischemic events, 9 stroke (5 lacunar infarctions, and 2 cardioembolic strokes), 10 diabetes mellitus, 4 chronic heart failure and 7 hospitalizations for cardiovascular reasons, newly onset chronic heart failure and diabetes mellitus.
Median of circulating MMP-9 in patients with recurrent cardiovascular events compared with those without it were 1059.50 ng / ml (95% CI = 801.19-1514.51 ng / ml) and 679.77 ng / ml (95% CI = 590.11-769.43 ng / mL), respectively (P <0.001). No significant differences between cohorts with MMP-9 levels regarding age, sex, type of acute ischemic stroke occurred, BP at the study entry, cardiovascular risk factors (BMI, dyslipidemia, low-density cholesterol, fasting glucose), initial NIHSS score, initial Barthel Index score, initial Rankin Scale score. Using ROC-analysis we found that the most optimal cutoff-point of circulating MMP-9 was 1001.0 ng / ml (sensitivity = 85.7%, specificity = 72.1%), area under the ROC curve was 0.814 (95% CI = 0.671-0.958; P = 0.001). Multivariant regression model has been showed that MMP-9 over 1001.0 ng / ml (R = 0.628; P = 0.001), high-sensitivity CRP (R = 0.522; P = 0.001), type 2 diabetes mellitus (R = 0.46; P = 0.001), and male sex (R = 0.41; P = 0.001) were independent predictors of cumulative cardiovascular events. Using Cox-regression analysis we found that patients with circulating MMP-9 over 1001.0 ng / ml compared with lower concentrations of MMP-9 had almost 3 time increased risk of recurrent cardiovascular outcomes within 1 year after stroke (Odds Ratio =2.78, 95% CI = 2.41-2.95; P = 0.001).
Results obtained by us support the hypothesis that circulating MMP-9 is an independent one-year predictor of cardiovascular outcomes including atherothrombotic events in hypertensive patients after serious ischemic brain event [7, 8] . However, this conclusion was valid for patients at very high cardiovascular risk with significantly incremented circulating levels of MMP-9 during six months of follow-up. We believe that incremented MMP-9 concentrations are not only associated with increased incidence of recurrent cardiovascular events, but they may be a reflection of the phenomenon of vascular remodeling progression in the long-term period. It should be noted that all patients included in the trial had controlled blood pressure, and the majority of them continued to receive ACE inhibitors, calcium channel blockers, statins and antiplatelet therapy after stroke. However, despite the use of statins, the target levels of LDL-C were not achieved in most patients. Taken into consideration the fact that statins are able to implement the anti-proliferative and anti-inflammatory effects, our findings can be interpreted as an indirect argument in favor of expanding the use of statins in hypertensive patients directly after stroke. This assumption needs to be confirmed in studies with greater statistical power. In conclusion, we found that increase of circulating MMP-9 in hypertensive patients after ischemic stroke had more much one-year predicted value for cardiovascular 8 Oxana A. Lisovaya recurrent events when compared with single concentrations of one taking during follow-up.
